Estado del arte en primera línea de CPNM en pacientes sin mutaciones Driver Monoterapia vs combinación

24 / 54

PFS 8.8 vs. 4.9 mo., HR: 0.52, p<0.0001
First-line CT ± Pembrolizumab for metastatic non-squamous NSCLC
KEYNOTE-189 trial
Gandhi L, et al. N Engl J Med 378:2078-2092, 2018
OS NR vs. 11.3 mo., HR: 0.49, p<0.0001
RR: 47.6% vs. 18.9%, p<0.001
FDA approval on 21st August 2018
EMA approval on 4th September 2018